AX-003

About axelyf

Axelyf is a private, preclinical-stage biotech leveraging its proprietary AXL lipid nanoparticle platform and ANNA™ AI model to develop next-generation RNA therapeutics. Its lead programs target significant unmet needs in solid tumors (AX-004, an in vivo CAR-T) and autoimmune hepatitis (AX-003). The company operates a dual strategy of building its own asset pipeline and licensing its tunable LNP technology to partners, positioning itself at the intersection of advanced drug delivery and AI-driven design.

Therapeutic Areas

Other Autoimmune Hepatitis Drugs